Technical Analysis for ZYME - Zymeworks Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 1.99% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 1.99% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.99% | |
| 200 DMA Support | Bullish | 1.99% | |
| Inside Day | Range Contraction | 1.99% | |
| Overbought Stochastic | Strength | 1.99% | |
| 200 DMA Support | Bullish | 1.32% | |
| Pocket Pivot | Bullish Swing Setup | 1.32% | |
| Outside Day | Range Expansion | 1.32% | |
| Overbought Stochastic | Strength | 1.32% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 1 hour ago |
| Up 3% | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Up 2% | about 3 hours ago |
| Up 1% | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/02/2024
Zymeworks Inc. Description
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Cancer Immunotherapy Monoclonal Antibodies Antibody Toxins Glycoproteins Her2 Protein Engineering Biological Systems Bispecific Monoclonal Antibody
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.14 |
| 52 Week Low | 6.015 |
| Average Volume | 455,535 |
| 200-Day Moving Average | 8.88 |
| 50-Day Moving Average | 9.95 |
| 20-Day Moving Average | 8.82 |
| 10-Day Moving Average | 8.75 |
| Average True Range | 0.44 |
| RSI (14) | 47.64 |
| ADX | 30.77 |
| +DI | 15.86 |
| -DI | 18.51 |
| Chandelier Exit (Long, 3 ATRs) | 8.33 |
| Chandelier Exit (Short, 3 ATRs) | 9.29 |
| Upper Bollinger Bands | 9.48 |
| Lower Bollinger Band | 8.15 |
| Percent B (%b) | 0.68 |
| BandWidth | 15.18 |
| MACD Line | -0.23 |
| MACD Signal Line | -0.37 |
| MACD Histogram | 0.1436 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.74 | ||||
| Resistance 3 (R3) | 9.75 | 9.54 | 9.62 | ||
| Resistance 2 (R2) | 9.54 | 9.37 | 9.53 | 9.58 | |
| Resistance 1 (R1) | 9.30 | 9.26 | 9.20 | 9.29 | 9.55 |
| Pivot Point | 9.09 | 9.09 | 9.04 | 9.08 | 9.09 |
| Support 1 (S1) | 8.85 | 8.92 | 8.75 | 8.84 | 8.57 |
| Support 2 (S2) | 8.64 | 8.81 | 8.63 | 8.54 | |
| Support 3 (S3) | 8.40 | 8.64 | 8.50 | ||
| Support 4 (S4) | 8.39 |
